Cirrus Therapeutics

Cirrus Therapeutics is dedicated to advancing the field of ocular immunology, focusing on the development of innovative treatments for chronic blinding diseases. With a commitment to addressing the complexities of the ocular immune system, Cirrus Therapeutics is at the forefront of biotechnology research, striving to improve the lives of patients suffering from long-term eye conditions.

Cirrus Therapeutics' lead program offers a differentiated and first-in-class approach to treating dry age-related macular degeneration (AMD), the leading cause of vision loss among older adults. By targeting multiple pathways involved in treating AMD, Cirrus Therapeutics is developing solutions that hold the potential to significantly protect against retinal degeneration and improve upon current treatment strategies.

Cirrus Therapeutics is committed to innovation and excellence in the biotechnology sector. The company is poised to make a significant impact on the AMD market, which is expected to reach $27.5 billion by 2031. Cirrus Therapeutics is dedicated to pioneering evidence-based strategies that offer the most compelling solutions for patients worldwide.

We invite the manager of Cirrus Therapeutics to create a customized and exclusive company showcase and product listing on our platform.